Clinical trials: Irritable Colon
Irritable Bowel Syndrome
Vetal Laban Intervention Trial Assessing Bowel Symptoms
A two month intervention trial assessing the effect of Vetal Laban containing L. acidophilus on enhancing functional bowel wellbeing among subjects with irritable bowel syndrome (IBS).
- Trial name
- KF_2013 (NCT01887483)
- Testing
- Vetal Laban active
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Danisco
Colonic Cancer, Colonic Polyp
Split-dose Versus Single-dose Bowel Preparation for Colonoscopy
Colonoscopy is the current standard method for evaluation of colonic disorders such as colorectal cancer, IBD, polyps, and other conditions.
- Conditions
- Colonic Cancer, Colonic Polyp, IBS - Irritable Bowel Syndrome
- Trial name
- NCT06426745
- Testing
- Bowel preparation
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Egymedicalpedia
Irritable Bowel Syndrome
Irritable Bowel Syndrome and Lactibiane Tolerance
The purpose of this study is to evaluate the effects of a probiotic combination (Lactibiane Tolerance) on the severity of symptoms in patients with irritable bowel syndrome (IBS).
- Trial name
- NCT01529359
- Testing
- Lactibiane Tolerance
- Where
- France
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- PiLeJe
IBS (Irritable Bowel Syndrome)
A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS).
- Trial name
- NCT07540312
- Testing
- Variable Compression System
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- PGP Health
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Irritable Colon
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
The purpose of this study is to see if GW876008 in Irritable Bowel Syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.
- Trial name
- NCT00385099
- Testing
- GW876008
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs).
- Trial name
- NCT02590432
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Non-constipation Irritable Bowel Syndrome
Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome
The purpose of this study is to determine the efficacy and safety of different doses of SKI3246 compared with placebo in the treatment of patients with irritable bowel syndrome with non-constipation.
- Trial name
- NCT02079675
- Testing
- SKI3246 Low Dose, SKI3246 High Dose
- Where
- South Korea
- Volunteers
- 279 people
- Sponsor
- SK Chemicals Co., Ltd.
Irritable Bowel Syndrome
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.
- Trial name
- NCT02544152
- Testing
- Lubiprostone
- Where
- 16 sites in United States
- Volunteers
- 71 people
- Sponsor
- Sucampo Pharma Americas, LLC
Irritable Bowel Syndrome
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: Strategy A = MeteoSpasmyl®, on-demand therapy Strategy B = standard of care chosen by the physician
- Trial name
- NCT01404923
- Testing
- anti spasmodic agents, alverine citrate, simeticone
- Volunteers
- 436 people
- Sponsor
- Laboratoires Mayoly Spindler
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease…
- Trial name
- GIANT (NCT06681012)
- Testing
- Gelsectan®
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 330 people
- Sponsor
- Devintec Sagl
Irritable Bowel Syndrome
8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
In this study, female patients with IBS-d will be treated for 8 weeks to assess the safety and effectiveness of DDP225 on GI transit and in reducing IBS symptoms.
- Trial name
- NCT00230581
- Testing
- DDP225
- Where
- 16 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Dynogen Pharmaceuticals
Diarrhea
Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.
This study aims to assess elemental impurities level after dministration of dioctahedral smectite in subjects with functional diarrhea or irritable bowel syndrome with predominant diarrhea.
- Trial name
- NCT05816681
- Testing
- DWJ1230, DWB2001
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Irritable Bowel Syndrome
Sucrose Breath Test to Determine Intestinal Permeability in IBS
Irritable Bowel Syndrome (IBS) is a growing clinical diagnosis affecting 10-20% of the US population. While current diagnostic criteria aids in correctly diagnosing IBS, the cause of the disease still remains unclear.
- Trial name
- NCT01674088
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Metabolic Solutions Inc.
IBS - Irritable Bowel Syndrome
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.
- Trial name
- NCT05178017
- Testing
- Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oxford Biomedical Technologies, Inc.
Irritable Bowel Syndrome, Diarrhea
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D).
- Trial name
- RENEW-IBS-D (NCT07545759)
- Testing
- LY3537031
- Where
- 89 sites in United States, Belgium and 8 more
- Volunteers
- 531 people
- Sponsor
- Eli Lilly and Company
Irritable Bowel Syndrome Characterized by Constipation
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
- Trial name
- CIBS (NCT01722318)
- Testing
- Plecanatide
- Where
- 99 sites in United States
- Volunteers
- 428 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
The current study is designed to assess the safety, tolerability, pharmacokinetics (PK), gastrointestinal (GI) transit time and pharmacodynamic (PD) biomarkers of repeat oral doses of GSK3179106 administered for 14 days in normal…
- Trial name
- NCT02798991
- Testing
- GSK3179106
- Where
- Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome (IBS)
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.
- Trial name
- NCT00401479
- Testing
- Solabegron (GW427353)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline